There is a continuing need for improved minimally invasive delivery of therapeutic agents to all portions of the respiratory system, particularly the lungs, bronchi and bronchioli, blood vessels, and lymphatic system. There is also a continuing need for improved minimally invasive access to lung tissue and structures.
The airways in the lungs anatomically constitute an extensive network of conduits that reach all lung areas and lung tissues. The airways have extensive branching that distally communicates with the parenchyma alveoli where gas exchange occurs, and proximally with the trachea and atmosphere (air). Because of the physiological characteristics of the airways, a therapeutic agent placed in bronchi and bronchioli may be delivered focally, localized, or systemically depending on the agent and the manner in which it is placed.
Historically, there has been a limited use of airways for delivery of therapeutic agents, diagnostic procedures, and instrumentation for invasive procedures. The airways have successfully been used for delivery of certain small particle therapeutic agents, such as inhalers for asthma, administration of gas anesthesia, and for introduction of certain visual diagnostic tools in conjunction with a bronchoscope. Through the bronchoscope, a limited number of invasive procedures are now being performed, including biopsies and removal of foreign objects.
Treatment of certain lung diseases and conditions would benefit from targeted intra-bronchial delivery of therapeutic agents into the involved regions, particularly those associated with the lungs such as pneumonia and lung cancer. Treatment would be further benefited if the therapeutic agent is generally confined to the involved regions. For example, treatment of a disease such as pneumonia will benefit by being able to deliver an antibiotic to the specific lung region involved. Furthermore, treatment of lung cancer may benefit from non-invasive brachytherapy. However, the full potential use of the airways for delivery of therapeutic agents and invasive procedures has not been realized because current technology is not able to isolate selected portions of the airways and/or lung tissue where therapeutic agents or procedures are to be delivered.
In view of the foregoing, there is a need in the art for a new and improved device, system, and method for isolating selected portions of airways without adversely effecting lung function or structure while allowing delivery of a therapeutic agent, or instrumentation. However, no such device, system, or method presently exists. Aspects of the present invention are directed to providing such an improved device and method.
The present invention includes an intra-bronchial device, system, and method for providing a therapeutic agent to a patient. The invention provides an intra-bronchial device including a member arranged for placement in an air passageway, and a therapeutic agent associated with the member and arranged for provision to a patient. The member may be further arranged for inhibiting the therapeutic agent from moving proximal of the control member. The intra-bronchial device may further include at least one anchor that retains the intra-bronchial device within the air passageway when the anchor is deployed, and at least one anchor may be releasable from the air passageway for removal of the intra-bronchial device.
The invention also provides an assembly including a therapeutic agent arranged for intra-bronchial delivery into an air passageway of a patient, and a flow control member arranged for placement in the air passageway and inhibiting the therapeutic agent from moving proximal of the control member. The flow control member may be arranged to allow the therapeutic agent to be associated with the flow control member after the flow control member is placed in the air passageway. The flow control member may be arranged to allow the therapeutic agent to be placed into the air passageway distal of the flow control member after the flow control member is placed in the air passageway.
The invention further provides an intra-bronchial device for maintaining a therapeutic agent within an air passageway. The device includes a flow control member arranged for placement in the air passageway and inhibiting the therapeutic agent from moving proximal of the control member, and the therapeutic agent. The control member may inhibit movement of the therapeutic agent by limiting flow from the air passageway. The control member may inhibit movement of the therapeutic agent by limiting flow into the air passageway, which limitation may be by limiting mucociliary transport from the air passageway. The control member may include a one-way valve. The one-way valve may permit inhalation of air into the air passageway, or permit exhalation of air from the air passageway. The control member may include a flexible membrane impervious to air flow. The flexible membrane may be arranged in cooperation with a wall of the air passageway to form a one-way valve permitting airflow from the air passageway, or a one-way valve permitting airflow into the air passageway. The control member may include a separator arranged to inhibit the movement of the therapeutic agent while allowing movement of air. The molecules of the therapeutic agent may be associated with molecules larger than air molecules, and the separator arranged to inhibit movement of the associated molecules while allowing movement of air molecules. The control member may include a semi-permeable membrane arranged to retain the therapeutic agent distal of the control member while permitting air and water molecules to be exhaled. The control member may limit airflow from the air passageway sufficiently to maintain inflation of a lung portion communicating with the air passageway. The control member may allow airflow from the air passageway sufficiently to prevent over-inflation of the lung portion. The control member may further include at least one anchor that retains the intra-bronchial device within the air passageway when the anchor is deployed, and at least one anchor may be releasable from the air passageway for removal of the intra-bronchial device. The control member may be further arranged to automatically terminate the inhibiting of movement by the therapeutic agent. The automatic termination may be provided by deterioration of the control member, or by dissolution of the control member.
The control member may be further arranged to permit mucociliary transport from the air passageway. The therapeutic agent may be associated with at least a portion of the control member. The therapeutic agent may overlie at least a portion of the airflow control member, may be imbedded in at least a portion of the airflow control member, may be absorbed in at least a portion of the airflow control member, and/or may be co-mixed with at least a portion of the airflow control member. The control member further includes an absorptive member and the therapeutic agent is absorbed by the absorptive member. The control member may include a cavity, and the therapeutic agent carried in the cavity. The cavity may include an absorptive member, and the therapeutic agent absorbed by the absorptive member. The cavity may included a cover having an orifice. The therapeutic agent may be one of antimicrobial agents such as adrenergic agents, antibiotic agents or antibacterial agents, antiviral agents, anthelmintic agents, anti-inflammatory agents, antineoplastic agents, antioxidant agents, biological reaction inhibitors, botulinum toxin agents, chemotherapy agents, diagnostic agents, gene therapy agents, hormonal agents, mucolytic agents, radioprotective agents, radioactive agents including brachytherapy materials, tissue growth inhibitors, tissue growth enhancers, and vasoactive agents.
The invention still further provides a system for intra-bronchially providing a therapeutic agent to a patient. The system includes an intra-bronchial device including a flow control device arranged for placement in an air passageway, and when deployed, limits flow from the air passageway sufficiently to inhibit a therapeutic agent distal of the control member from moving proximal, and an introducer that introduces the therapeutic agent in the lung portion distal of the airflow control member.
The invention yet still further provides a method for providing a therapeutic agent to a patient. The method may include the steps of delivering a therapeutic agent to a lung portion, and inhibiting movement of the therapeutic agent from the lung portion. The inhibiting step may include the further step of limiting airflow from the lung portion to inhibit therapeutic agent distal of the control member from moving proximal. The method may include the further step of maintaining an inflation of the lung portion. The method may include the further step of maintaining a collapse of the lung portion. The delivering step may be performed with one intra-bronchial device and the inhibiting step is performed with another intra-bronchial device. The method may include the further step of performing the delivering step again. The inhibiting step may include the further step of implanting an intra-bronchial device in an air passageway in communication with the lung portion. The delivery step may include providing the therapeutic agent to the intra-bronchial device. The method may include the further step of terminating the inhibition of movement. The therapeutic agent may be one of antimicrobial agents such as adrenergic agents, antibiotic agents or antibacterial agents, antiviral agents, anthelmintic agents, anti-inflammatory agents, antineoplastic agents, antioxidant agents, biological reaction inhibitors, botulinum toxin agents, chemotherapy agents, diagnostic agents, gene therapy agents, hormonal agents, mucolytic agents, radioprotective agents, radioactive agents including brachytherapy materials, tissue growth inhibitors, tissue growth enhancers, and vasoactive agents.
The invention also provides an intra-bronchial device for providing a therapeutic agent to a patient. The device including means for delivering a therapeutic agent into an air passageway of the patient, and means for intra-bronchially inhibiting movement of the therapeutic agent from the air passageway. The movement may be inhibited by limiting exhalation from the air passageway, by limiting inhalation into the air passageway, and/or by limiting movement of mucus from the air passageway.
The features of the present invention which are believed to be novel are set forth with particularity in the appended claims. The invention, together with further objects and advantages thereof, may best be understood by making reference to the following description taken in conjunction with the accompanying drawings, in the several figures of which like referenced numerals identify identical elements, and wherein:
a illustrates the device of
b illustrates the device of
In the following detailed description of exemplary embodiments of the invention, reference is made to the accompanying drawings that form a part hereof. The detailed description and the drawings illustrate specific exemplary embodiments by which the invention may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention. It is understood that other embodiments may be utilized, and other changes may be made, without departing from the spirit or scope of the present invention. The following detailed description is therefore not to be taken in a limiting sense, and the scope of the present invention is defined by the appended claims.
Throughout the specification and claims, the following terms take the meanings explicitly associated herein unless the context clearly dictates otherwise. The meaning of “a”, “an”, and “the” include plural references. The meaning of “in” includes “in” and “on.” Referring to the drawings, like numbers indicate like parts throughout the views. Additionally, a reference to the singular includes a reference to the plural unless otherwise stated or inconsistent with the disclosure herein. Additionally, throughout the specification, claims, and drawings, the term “proximal” means nearest the trachea, and “distal” means nearest the alveoli.
The respiratory system 20 includes trachea 28; left mainstem bronchus 30 and right mainstem bronchus 32 (primary, or first generation); and lobar bronchial branches 34, 36, 38, 40, and 42 (second generation).
A characteristic of a healthy respiratory system is the arched or inwardly arcuate diaphragm 26. As the individual inhales, the diaphragm 26 straightens to increase the volume of the thorax 22. This causes a negative pressure within the thorax. The negative pressure within the thorax in turn causes the lung lobes to fill with air. When the individual exhales, the diaphragm returns to its original arched condition to decrease the volume of the thorax. The decreased volume of the thorax causes a positive pressure within the thorax, which in turn causes exhalation of the lung lobes.
Another characteristic of the respiratory system is the mucus flow from the lungs, or mucociliary transport system. Many pollution particles are inhaled as a person breathes, and the air passageways function as a very effective filter. The mucociliary transport system functions as a self-cleaning mechanism for all air passageways, including the lungs. The mucociliary transport system is a primary method for mucus clearance from distal portions of the lungs, and further constitutes a primary immune barrier for the lungs. The surface of air passageways is formed with respiratory epithelium (or epithelial membrane), which is covered with cilia and coated with mucus. As part of the mucociliary transport system, the mucus entraps many inhaled particles and moves them toward the larynx 28. The mucociliary transport system includes the metachronal ciliary beat of cilia on the respiratory epithelium that moves a continuous carpet of mucus and entrapped particles from the distal portions of the lungs past the larynx 28 and to the pharynx for expulsion from the respiratory system. The mucociliary transport system will also function as a self-clearing mechanism removing therapeutic agents placed in a lung portion and entrapped by the mucus. Additional description of the mucociliary transport system is provided in INTRA-BRONCHIAL OBSTRUCTING DEVICE THAT PERMITS MUCUS TRANSPORT filed May 9, 2002, application Ser. No. 10/143,353, which is owned by the Assignee, and which is incorporated herein by reference.
The air passageways branch out, much like the roots of a tree. The bronchial segments branch into six generations or orders, and the bronchioles branch into approximately another three to eight generations or orders. Typically, each generation has a smaller diameter than its predecessor. The inside diameter of a generation varies depending on the particular bronchial branch, and further varies between individuals. For example, a typical lobar bronchus 42 (third generation) providing air circulation to the upper right upper lobe 56 has an internal diameter of approximately 1 cm. A typical segmental bronchi 48 (fourth generation) has an internal diameter of approximately 4 to 7 mm. The fifth and sixth generations (no reference numbers) are each proportionately smaller. The bronchial segments include annular ligaments and irregularly located cartilages that provide structure and resilience. The cartilages become increasingly sparse as the bronchial segments become smaller in diameter. The bronchioles do not have ligaments and cartilages. Furthermore, the inside diameters of air passageways is not static. They expand when a person inhales and contract when a person exhales.
The control member 90 may be any shape and composed of any material suitable for accomplishing its purpose. Possible shapes include spherical, cylindrical, oval, and conical. For example, control member 90 may be a conical shaped plug arranged to inhibit proximal movement of a therapeutic agent by sealing air passageway 50 against proximal flow of air and mucus. Control member 90 may be a solid member, a composition of materials, or a membrane that retains a shape or is carried on a frame. More specifically, the control member 90 has an outer dimension 91, and when expanded, enables contact with an air passageway inner dimension 51. The contact may be arranged in any manner to inhibit a therapeutic agent distal of the control member 90 from moving proximal to control member 90. As used in this specification, including the description and claims, the meaning of word “inhibit” and its derivatives, such as “inhibiting,” include reducing, diminishing, hindering, restraining, preventing, precluding, or prohibiting, unless otherwise indicated.
The intra-bronchial device is described in this specification, including the detailed description and the claims, in terms of limiting flow from a lung portion communicating with an air passageway. In some lungs, a portion of a lung may receive air from collateral air passageways. Controlling the airflow or mucociliary transport in one of the collateral air passageways may reduce the flow from the lung portion communicating with that air passageway, but may not completely control flow from the lung portion.
Once the control member 90 is paced in the air passageway 50, a final step includes releasing the therapeutic agent 105 distal of the control member 90. Catheter 70 may be used to discharge therapeutic agent 105, or another thin catheter arranged for delivery of the therapeutic agent 105 may be used. The tip 77 of catheter 70 is guided between the exterior perimeter surface 98 and the bronchial wall 100, and advanced until tip 77 is distal of control member 90. The therapeutic agent 105 is released from the tip 77, and the catheter 70 is withdrawn from the patient. Additional doses of the therapeutic agent 105 may be administered by again placing a delivery catheter in the air passageway 50 and releasing additional therapeutic agent 105 distal of the control member 90.
In an alternative embodiment, the therapeutic agent 105 may be released first, and the control member 90 then placed in the air passageway 50 in position to inhibit movement of the therapeutic agent 105. In a further alternative embodiment, the control member 90 may be made of a self-sealing, pierceable material, such as a membrane, and the tip 77 arranged to pierce through the control member 90 and discharge the therapeutic agent 105 distal of the control member 90. In yet a further embodiment, the control member 90 may include an absorbable material, and the tip 77 arranged to discharge the therapeutic agent 105 into the absorbable material for release from the absorbable material distal of the control member 90.
In another embodiment, control member 90 may include a plurality of longitudinal ribs (not shown) on the outer peripheral surface 91. When the control member 90 is placed in the air passageway 50, the ribs and the interior wall of the air passageway define at least one peripheral flow pathway. The dimensioning and spacing of the longitudinal ribs may be selected to define the size of the peripheral flow pathway, and the degree to which airflow and/or mucociliary transport are inhibited. The larger a flow pathway, the less a flow will be limited.
In a still further alternative embodiment, the control member 90 is arranged to automatically terminate inhibition of proximal movement of the therapeutic agent 105. The inhibition may be automatically terminated by a dissolving, deteriorating, or other structural characteristic that causes the control member 90 to terminate forming a seal with the air passageway wall 100 without any outside act or step being taken. For example, all or a portion of the control member 90 may be made from a foam material arranged to dissolve or deteriorate after a predetermined length of time. Alternatively, all or a portion of control member 90 may be made from a sugar that will dissolve after a predetermined length of time. By way of further example, control member 90 may be arranged to dissolve or deteriorate after several days in the air passageway 50. This could allow treatment of localized pneumonia by isolating the involved lung portion with the control member 90. An antibiotic agent suitable for treating pneumonia may be placed in the lung portion 66, and retained in the lung portion by control member 90 for several days. After that period of time, the control member 90 would automatically deteriorate or dissolve, and be removed from the air passageway 50 by absorption, mucociliary transport, coughing, or some other mechanism without outside action. This would terminate the isolation and return the lung portion to normal functioning.
The term “therapeutic agent” is broadly used in this specification, including the description and claims, and includes anything presented for treatment, curing, mitigating, or preventing deleterious conditions in humans and animals. The term “therapeutic agent” also includes substances and agents for combating a disease, condition, or disorder of a patient, and includes drugs, diagnostics, and instrumentation.
“Therapeutic agent” also includes anything used in medical diagnosis, or in restoring, correcting, or modifying physiological functions. The term “therapeutic agent” may also mean a medicant or a medicine.
The therapeutic agent is selected according to the treatment objective and biological action desired. General classes of therapeutic agents include anti-microbial agents such as adrenergic agents, antibiotic agents or antibacterial agents, antiviral agents, anthelmintic agents, anti-inflammatory agents, antineoplastic agents, antioxidant agents, biological reaction inhibitors, botulinum toxin agents, chemotherapy agents, diagnostic agents, gene therapy agents, hormonal agents, mucolytic agents, radioprotective agents, radioactive agents including brachytherapy materials, tissue growth inhibitors, tissue growth enhancers, and vasoactive agents.
The therapeutic agent may be selected from any class suitable for the therapeutic objective. For example, if the objective is treating a disease or condition associated with lungs such as acute or chronic pneumonia, the therapeutic agent may include antibiotics such as penicillin, ceftriaxone, tobramycin, vancomycin. By way of further example, if the desired treatment objective is treatment of cancer in lung or nearby tissue, the therapeutic agent may include radioactive material in the form of radioactive seeds providing radiation treatment directly into the tumor or close to it. Further, the therapeutic agent may be selected or arranged to provide therapeutic activity over a period of time.
In accordance with a broad aspect of the present invention, the therapeutic agent 105 may be associated with the control member 90 of an intra-bronchial device in any manner known in the art suitable for release or provision to the patient. An embodiment of the invention is arranged to release of therapeutic agent 105 distal of the intra-bronchial device for providing focal and systemic treatments. Other embodiments are arranged to provide the therapeutic agent 105 to the tissue contact area between the intra-bronchial and the wall of the air passageway 100.
Therapeutic agent 105 may be associated with all or any portion of the control member 90 in any manner known to those skilled in the art, and as required by the therapeutic action desired and the limitations of the selected therapeutic agent 105. Association methods include overlayment, absorption, and imbedding, which may be by any method known to those in the art, including spraying, dipping, ion implantation, and painting. Alternative embodiments of the invention may include associating therapeutic agent 105 by impregnation, co-mixing, or absorption into control member 90 in any manner known to those skilled in the art, and as required by therapeutic action desired and the limitations of the selected therapeutic agent 105. Co-mixing includes combining the therapeutic agent 105 with a carrier or the material of control member 90 in such a manner that the therapeutic agent 105 is releasable from the mix. An antimicrobial therapeutic agent 105 may be absorbed into at least a portion of control member 90.
An aspect of the invention and a flow control member, such as control member 90, is directed toward targeted intra-bronchial delivery of a therapeutic agent that treats diseases and conditions of the patient, particularly those associated with the lungs such as inflammatory, infectious, and neoplastic diseases. Treatment of certain lung diseases and conditions will benefit from targeted intra-bronchial delivery of a therapeutic agent 105 into the involved regions. Treatment will be further benefited if the therapeutic agent 105 is generally confined to the involved regions. For example, treatment of pneumonia will benefit by being able to deliver an antibiotic to the specific lung region involve. Treatment will also be benefited by isolating the involved lung portion to prevent disease dissemination. By inhibiting exhalation and/or mucociliary transport, control member 90 meets these treatment goals by generally confining the therapeutic agent to the lung portion, and by isolating the lung portion to prevent disease dissemination. Depending on the course of treatment desired, control member 90 may be arranged to allow the lung portion to be or remain inflated by allowing inhalation airflow and limiting exhalation airflow, or to collapse the lung portion by limiting inhalation airflow.
Still further, the therapeutic agent may be associated with an element of an intra-bronchial device, which in turn is coupled to control member 90. Such elements may include structural members, or anchors for example. The therapeutic agent may be associated with control member 90 either before or after it is inserted into air passageway 50, or renewed after insertion.
In another embodiment, the cavity 110 of control member 90 may include an absorptive member (not shown) that carries the therapeutic agent 105. The absorptive member may occupy all or at least a portion of the cavity 110. The absorptive member may be any material and any configuration known to those skilled in the art, and as required by the limitations of selected therapeutic agent 105.
The one-way valve may be centrally positioned in the control member 120. Control member 120 includes a generally circular base 134 and a circumferential generally cylindrical sidewall 136. Control member 120 further includes resilient reinforcement rib 130. To form the one-way valve, the base 134 is made from a resilient material, and includes a slit 122 to form a valving structure. On either side of the slit 122 is a tether 124 and 126, which extend to the resilient reinforcement rib 130. As illustrated in
The contact between the outer dimension 91 and air passageway inner dimension 51 may be arranged to form a mucus seal stopping or limiting proximal mucus movement. The one-way valve will limit airflow from the lung portion 66 and maintain it in an inflated condition. Any therapeutic agent 105 released distally of control member 90 will be inhibited from moving proximally by the one-way valve and the mucus seal.
An aspect of the invention provides for arranging and carrying therapeutic agent 105 on a distal portion of a control member in a manner to promote intra-bronchial delivery.
The structure of anchored intra-bronchial device 200 includes support structure 201 and a control member 290. Support structure 201 includes a central support structure 209, an anchor base 261, and optionally control member support members 202, 203, 204, 205, 206 and 208. The anchor base 261 includes an anchor base aperture 265, anchor base angle 263, and anchors 212, 214, and 216, which include anchor ends 222, 224, and 226, and stops 252, 254, and 256, respectively. Central support structure 209 extends both proximal and distal of control member 290, and carries anchor base 261 proximal of control member 290. Central support structure 209 also distally carries the cavity 110 that is arranged for carrying the therapeutic agent 105. The linear plane of anchors 212, 214, and 216 intersect anchor base 261 at anchor base angle 263. Anchor base angle 263 is selected to optimize anchor deployment force and anchor releaseability. Stops 252, 254, and 256 include a flat area to limit the piercing of the air passageway wall by anchor ends 222, 224, and 226. In alternative embodiments, the stops can be any configuration or shape known to those skilled in the art to limit the piercing.
The anchors 212, 214, and 216 are arranged to be collapsible into a configuration for being fed through the conduit 70 in a collapsed state, and to move to an anchoring configuration upon deployment in the air passageway 50 for engaging the interior wall of the air passageway 50. The anchors are further arranged to be releaseable from the interior wall of the air passageway by engaging the intra-bronchial device 200 with an instrument, and drawing device 200 into the conduit 70 and removing it from the patient. The Applications for Anchored Devices provide additional descriptions of anchored structures, of anchoring an intra-bronchial device in an air passageway, and of releasing the anchors and removing the intra-bronchial device from an air passageway.
Flow control member 290 is similar to flow control member 90. Flow control member 290 may be formed of a flexible membrane or a solid material, is generally impervious to airflow, and may be formed of a silicone or polyurethane, for example. Flow control member 290 may have any shape suitable for accomplishing its purpose, and optimally is collapsible to enable it to be fed through the conduit 70 in a collapsed state. Control member 290 may either be supported by its own structure, or may be carried on and supported by control member support members, such as members 202, 203, 204, 205, 206 and 208. Control member 290 is arranged to be carried on the support structure 201, and to have its generally circular base orientated distally. Control member 290 is secured to the central support structure 109, and may be additionally secured to the support members at its larger diameter 91. It may be secured by adhesive, or other manner known in the art. Control member 290 may be structurally arranged, or loosely carried on support members 102, 103, 104, 105, 106, and 108, such that it expands radially outwardly when airflow is directed toward the generally circular base 94 to form a seal against the wall of the air passageway 50 and limits air and mucus flow. Control member 290 may be further structurally arranged to contract when the airflow reverses to diminish or break the seal and permit airflow. While
Control member 290 may include a separator or filtration element, or semi-permeable membrane, arranged to allow movement of air and water vapor molecules, but to inhibit movement of larger molecules and mucociliary transport. For example, a separator element such as a NUCLEPORE® polycarbonate track etch membrane, a registered trademark of Whatman, Inc., of Newton, Mass., could be used for all or a portion of the control member 290. The molecules of the therapeutic agent 105 are associated with molecules larger than air and water molecules, and the separator is arranged to inhibit movement of the larger associated molecules while allowing movement of the smaller air and water vapor molecules.
Use of multiple cooperating intra-bronchial devices as illustrated in
Intra-bronchial device 300 may be any member that does not significantly obstruct flow of air. For example, the intra-bronchial device carrying therapeutic agent 105 may be a tubular member coated with therapeutic agent 105, which may be balloon expandable as is known in the art, or may be self-expanding.
Additional intra-bronchial devices and methods for providing a therapeutic agent to a patient are disclosed and claimed in INTRA-BRONCHIAL AIRFLOW CONTROL DEVICE THAT CONTROLS BIOLOGICAL INTERACTION WITH THE PATIENT filed Feb. 21, 2002, application Ser. No. 10/081,712; and INTRA-BRONCHIAL AIRFLOW CONTROL DEVICE THAT CONTROLS BIOLOGICAL INTERACTION WITH THE PATIENT filed Jun. 21, 2002, application Ser. No. 10/178,073, which are incorporated herein by reference.
While particular embodiments of the present invention have been shown and described, modifications may be made, and it is therefore intended in the appended claims to cover all such changes and modifications that fall within the true spirit and scope of the invention.
This application is a continuation of U.S. patent application Ser. No. 10/317,667 (now U.S. Pat. No. 6,929,637), filed on Dec. 11, 2002, which is a continuation-in-part of and claims priority based on United States applications entitled INTRA-BRONCHIAL AIRFLOW CONTROL DEVICE THAT CONTROLS BIOLOGICAL INTERACTION WITH THE PATIENT filed Feb. 21, 2002, application Ser. No. 10/081,712 now abandoned; and INTRA-BRONCHIAL AIRFLOW CONTROL DEVICE THAT CONTROLS BIOLOGICAL INTERACTION WITH THE PATIENT filed Jun. 21, 2002, application Ser. No. 10/178,073 now abandoned. The entire contents of each of the above-noted prior patent applications are hereby incorporated by reference herein and made a part of this specification.
Number | Name | Date | Kind |
---|---|---|---|
2479805 | Sabaratnam | Aug 1949 | A |
2832078 | Williams | Apr 1958 | A |
2981254 | Vanderbilt | Apr 1961 | A |
3320972 | High et al. | May 1967 | A |
3370305 | Goott et al. | Feb 1968 | A |
3445916 | Schulte | May 1969 | A |
3472230 | Forgarty | Oct 1969 | A |
3540431 | Mobin-Uddin | Nov 1970 | A |
3617060 | Lezzi | Nov 1971 | A |
3657744 | Ersek | Apr 1972 | A |
3671979 | Moulopoulos | Jun 1972 | A |
3683913 | Kurtz et al. | Aug 1972 | A |
3757783 | Alley | Sep 1973 | A |
3760808 | Bleuer | Sep 1973 | A |
3788327 | Donowitz et al. | Jan 1974 | A |
3874388 | King et al. | Apr 1975 | A |
4014318 | Dockum et al. | Mar 1977 | A |
4040428 | Clifford | Aug 1977 | A |
4056854 | Boretos et al. | Nov 1977 | A |
4084268 | Ionescu et al. | Apr 1978 | A |
4086665 | Poirier | May 1978 | A |
4212463 | Repinski et al. | Jul 1980 | A |
4218782 | Rygg | Aug 1980 | A |
4222126 | Boretos et al. | Sep 1980 | A |
4250873 | Bonnet | Feb 1981 | A |
4301810 | Belman | Nov 1981 | A |
4302854 | Runge | Dec 1981 | A |
4339831 | Johnson | Jul 1982 | A |
RE31040 | Possis | Sep 1982 | E |
4403616 | King | Sep 1983 | A |
4456016 | Nowacki et al. | Jun 1984 | A |
4512338 | Balko et al. | Apr 1985 | A |
4533137 | Sonne | Aug 1985 | A |
4569674 | Phillips et al. | Feb 1986 | A |
4582058 | Depel et al. | Apr 1986 | A |
4592741 | Vincent | Jun 1986 | A |
4601465 | Roy | Jul 1986 | A |
4610256 | Wallace | Sep 1986 | A |
4619246 | Molgaard-Nielsen et al. | Oct 1986 | A |
4654027 | Dragan et al. | Mar 1987 | A |
4654029 | D'Antonio | Mar 1987 | A |
4681110 | Wiktor | Jul 1987 | A |
4684363 | Ari et al. | Aug 1987 | A |
4685908 | Kurtz | Aug 1987 | A |
4710192 | Liotta et al. | Dec 1987 | A |
4727873 | Mobin-Uddin | Mar 1988 | A |
4732152 | Wallsten et al. | Mar 1988 | A |
4745925 | Dietz | May 1988 | A |
4759758 | Gabbay | Jul 1988 | A |
4795449 | Schneider et al. | Jan 1989 | A |
4808183 | Panje | Feb 1989 | A |
4819664 | Nazari | Apr 1989 | A |
4822354 | Elosegui | Apr 1989 | A |
4830003 | Wolff et al. | May 1989 | A |
4832680 | Haber et al. | May 1989 | A |
4846836 | Reich | Jul 1989 | A |
4850999 | Planck | Jul 1989 | A |
4852568 | Kensey | Aug 1989 | A |
4877025 | Hanson | Oct 1989 | A |
4908028 | Colon et al. | Mar 1990 | A |
4934999 | Bader | Jun 1990 | A |
4936823 | Colvin et al. | Jun 1990 | A |
4968294 | Salama | Nov 1990 | A |
4973047 | Norell | Nov 1990 | A |
4979505 | Cox | Dec 1990 | A |
4984581 | Stice | Jan 1991 | A |
5033312 | Stupecky | Jul 1991 | A |
5038621 | Stupecky | Aug 1991 | A |
5059208 | Coe et al. | Oct 1991 | A |
5061274 | Kensey | Oct 1991 | A |
5078739 | Martin | Jan 1992 | A |
5092781 | Casciotti et al. | Mar 1992 | A |
5116360 | Pinchuk et al. | May 1992 | A |
5116564 | Jansen et al. | May 1992 | A |
5123919 | Sauter et al. | Jun 1992 | A |
5135488 | Foote et al. | Aug 1992 | A |
5151105 | Kwan-Gett | Sep 1992 | A |
5158548 | Lau et al. | Oct 1992 | A |
5161524 | Evans | Nov 1992 | A |
5171299 | Heitzmann et al. | Dec 1992 | A |
5197980 | Gorshkov et al. | Mar 1993 | A |
5255687 | McKenna | Oct 1993 | A |
5275169 | Afromowitz et al. | Jan 1994 | A |
5283063 | Freeman | Feb 1994 | A |
5300050 | Everett, Jr. et al. | Apr 1994 | A |
5304199 | Myers | Apr 1994 | A |
5306234 | Johnson | Apr 1994 | A |
5314473 | Godin | May 1994 | A |
5339805 | Parker | Aug 1994 | A |
5342298 | Michaels | Aug 1994 | A |
5352240 | Ross | Oct 1994 | A |
5353470 | Bartlett | Oct 1994 | A |
5358518 | Camilli | Oct 1994 | A |
5366478 | Brinkerhoff et al. | Nov 1994 | A |
5370657 | Irie | Dec 1994 | A |
5382261 | Palmaz | Jan 1995 | A |
5383470 | Kolbly | Jan 1995 | A |
5391205 | Knight | Feb 1995 | A |
5392775 | Adkins, Jr. et al. | Feb 1995 | A |
5398844 | Zaslavsky et al. | Mar 1995 | A |
5409019 | Wilk | Apr 1995 | A |
5409444 | Kensey et al. | Apr 1995 | A |
5411507 | Heckele | May 1995 | A |
5411552 | Andersen et al. | May 1995 | A |
5413599 | Imachi et al. | May 1995 | A |
5415660 | Campbell et al. | May 1995 | A |
5417226 | Juma | May 1995 | A |
5421325 | Cinberg et al. | Jun 1995 | A |
5445626 | Gigante | Aug 1995 | A |
5453090 | Martinez et al. | Sep 1995 | A |
5459544 | Emura | Oct 1995 | A |
5484444 | Braunschweiler et al. | Jan 1996 | A |
5486154 | Kelleher | Jan 1996 | A |
5499995 | Teirstein | Mar 1996 | A |
5500014 | Quijano et al. | Mar 1996 | A |
RE35225 | Herweck et al. | Apr 1996 | E |
5507754 | Green et al. | Apr 1996 | A |
5507797 | Suzuki et al. | Apr 1996 | A |
5509900 | Kirkman | Apr 1996 | A |
5514153 | Bonutti | May 1996 | A |
5549626 | Miller et al. | Aug 1996 | A |
5549628 | Cooper et al. | Aug 1996 | A |
5562608 | Sekins et al. | Oct 1996 | A |
5562641 | Flomenblit et al. | Oct 1996 | A |
5562728 | Lazarus et al. | Oct 1996 | A |
5603698 | Roberts et al. | Feb 1997 | A |
5607469 | Frey | Mar 1997 | A |
5645565 | Rudd et al. | Jul 1997 | A |
5647857 | Anderson et al. | Jul 1997 | A |
5660175 | Dayal | Aug 1997 | A |
5662713 | Andersen et al. | Sep 1997 | A |
5669933 | Simon et al. | Sep 1997 | A |
5676671 | Inoue | Oct 1997 | A |
5683451 | Lenker et al. | Nov 1997 | A |
5690644 | Yurek et al. | Nov 1997 | A |
5693089 | Inoue | Dec 1997 | A |
5697968 | Rogers et al. | Dec 1997 | A |
5702343 | Alferness | Dec 1997 | A |
5702409 | Rayburn et al. | Dec 1997 | A |
5725519 | Penner et al. | Mar 1998 | A |
5752522 | Murphy | May 1998 | A |
5752965 | Francis et al. | May 1998 | A |
5755770 | Ravenscroft | May 1998 | A |
5763979 | Mukherjee et al. | Jun 1998 | A |
5782896 | Chen et al. | Jul 1998 | A |
5797920 | Kim | Aug 1998 | A |
5797960 | Stevens et al. | Aug 1998 | A |
5800339 | Salama | Sep 1998 | A |
5803078 | Brauner | Sep 1998 | A |
5810837 | Hofmann et al. | Sep 1998 | A |
5817101 | Fiedler | Oct 1998 | A |
5830217 | Ryan | Nov 1998 | A |
5833694 | Poncet | Nov 1998 | A |
5840081 | Andersen et al. | Nov 1998 | A |
5851232 | Lois | Dec 1998 | A |
5855587 | Hyon et al. | Jan 1999 | A |
5855597 | Jayaraman | Jan 1999 | A |
5855601 | Bessler et al. | Jan 1999 | A |
5876434 | Flomenblit et al. | Mar 1999 | A |
5876445 | Andersen et al. | Mar 1999 | A |
5911756 | Debry | Jun 1999 | A |
5925063 | Khosravi | Jul 1999 | A |
5944738 | Amplatz et al. | Aug 1999 | A |
5947997 | Pavcnik et al. | Sep 1999 | A |
5954636 | Schwartz et al. | Sep 1999 | A |
5954766 | Zadno-Azizi et al. | Sep 1999 | A |
5957949 | Leonhardt et al. | Sep 1999 | A |
5957978 | Blom | Sep 1999 | A |
5972009 | Fortier et al. | Oct 1999 | A |
5976158 | Adams et al. | Nov 1999 | A |
5976174 | Ruiz | Nov 1999 | A |
5984965 | Knapp et al. | Nov 1999 | A |
5989234 | Valerio et al. | Nov 1999 | A |
6003517 | Sheffield et al. | Dec 1999 | A |
6007575 | Samuels | Dec 1999 | A |
6009614 | Morales | Jan 2000 | A |
6010511 | Murphy | Jan 2000 | A |
6010525 | Bonutti et al. | Jan 2000 | A |
6020380 | Killian | Feb 2000 | A |
6027525 | Suh et al. | Feb 2000 | A |
6045560 | McKean et al. | Apr 2000 | A |
6051022 | Cai et al. | Apr 2000 | A |
6068635 | Gianotti | May 2000 | A |
6068638 | Makower | May 2000 | A |
6077291 | Das | Jun 2000 | A |
6079413 | Baran | Jun 2000 | A |
6083141 | Hougen | Jul 2000 | A |
6083255 | Laufer et al. | Jul 2000 | A |
6096027 | Layne | Aug 2000 | A |
6099551 | Gabbay | Aug 2000 | A |
6123663 | Rebuffat | Sep 2000 | A |
6132458 | Staehle et al. | Oct 2000 | A |
6135729 | Aber | Oct 2000 | A |
6135991 | Muni et al. | Oct 2000 | A |
6141855 | Morales | Nov 2000 | A |
6146357 | Addis | Nov 2000 | A |
6149664 | Kurz | Nov 2000 | A |
6162245 | Jayaraman | Dec 2000 | A |
6165179 | Cathcart et al. | Dec 2000 | A |
6168614 | Andersen et al. | Jan 2001 | B1 |
6168617 | Blaeser et al. | Jan 2001 | B1 |
6174307 | Daniel et al. | Jan 2001 | B1 |
6174323 | Briggs et al. | Jan 2001 | B1 |
6183520 | Pintauro et al. | Feb 2001 | B1 |
6193748 | Thompson et al. | Feb 2001 | B1 |
6200333 | Laufer | Mar 2001 | B1 |
6203551 | Wu | Mar 2001 | B1 |
6206918 | Campbell et al. | Mar 2001 | B1 |
6210338 | Afremov et al. | Apr 2001 | B1 |
6231587 | Makower | May 2001 | B1 |
6231589 | Wessman et al. | May 2001 | B1 |
6234996 | Bagaoisan et al. | May 2001 | B1 |
6238334 | Easterbrook, III et al. | May 2001 | B1 |
6240615 | Kimes et al. | Jun 2001 | B1 |
6241654 | Alferness | Jun 2001 | B1 |
6241678 | Afremov et al. | Jun 2001 | B1 |
6241758 | Cox | Jun 2001 | B1 |
6242472 | Sekins et al. | Jun 2001 | B1 |
6245102 | Jayaraman | Jun 2001 | B1 |
6258100 | Alferness et al. | Jul 2001 | B1 |
6264700 | Kilcoyne et al. | Jul 2001 | B1 |
6267775 | Clerc et al. | Jul 2001 | B1 |
6270527 | Campbell et al. | Aug 2001 | B1 |
6287290 | Perkins et al. | Sep 2001 | B1 |
6287334 | Moll et al. | Sep 2001 | B1 |
6293951 | Alferness et al. | Sep 2001 | B1 |
6299604 | Ragheb et al. | Oct 2001 | B1 |
6302893 | Limon et al. | Oct 2001 | B1 |
6312407 | Zadno-Azizi et al. | Nov 2001 | B1 |
6325777 | Zadno-Azizi et al. | Dec 2001 | B1 |
6325778 | Zadno-Azizi et al. | Dec 2001 | B1 |
6327772 | Zadno-Azizi et al. | Dec 2001 | B1 |
6328689 | Gonzalez et al. | Dec 2001 | B1 |
6338728 | Valerio et al. | Jan 2002 | B1 |
6350278 | Lenker et al. | Feb 2002 | B1 |
6355014 | Zadno-Azizi et al. | Mar 2002 | B1 |
6398775 | Perkins et al. | Jun 2002 | B1 |
6402754 | Gonzalez | Jun 2002 | B1 |
6416554 | Alferness et al. | Jul 2002 | B1 |
6425916 | Garrison et al. | Jul 2002 | B1 |
6428561 | Johansson-Ruden et al. | Aug 2002 | B1 |
6439233 | Geertsema | Aug 2002 | B1 |
6440164 | DiMatteo et al. | Aug 2002 | B1 |
6447530 | Ostrovsky et al. | Sep 2002 | B1 |
6454754 | Frank | Sep 2002 | B1 |
6458076 | Pruitt | Oct 2002 | B1 |
6458153 | Bailey et al. | Oct 2002 | B1 |
6471718 | Staehle et al. | Oct 2002 | B1 |
6471979 | New et al. | Oct 2002 | B2 |
6485407 | Alferness et al. | Nov 2002 | B2 |
6488673 | Laufer et al. | Dec 2002 | B1 |
6491706 | Alferness et al. | Dec 2002 | B1 |
6493589 | Medhkour et al. | Dec 2002 | B1 |
6503272 | Duerig et al. | Jan 2003 | B2 |
6510846 | O'Rourke | Jan 2003 | B1 |
6514290 | Loomas | Feb 2003 | B1 |
6527761 | Buch et al. | Mar 2003 | B1 |
6540782 | Snyders | Apr 2003 | B1 |
6544192 | Starr et al. | Apr 2003 | B2 |
6544291 | Taylor | Apr 2003 | B2 |
6558429 | Taylor | May 2003 | B2 |
6568387 | Davenport et al. | May 2003 | B2 |
6569166 | Gonzalez | May 2003 | B2 |
6585639 | Kotmel et al. | Jul 2003 | B1 |
6589256 | Forber | Jul 2003 | B2 |
6592594 | Rimbaugh et al. | Jul 2003 | B2 |
6599311 | Biggs et al. | Jul 2003 | B1 |
6600307 | Turski et al. | Jul 2003 | B2 |
6610043 | Ingenito | Aug 2003 | B1 |
6629951 | Laufer et al. | Oct 2003 | B2 |
6632243 | Zadno-Azizi et al. | Oct 2003 | B1 |
6634363 | Laufer et al. | Oct 2003 | B1 |
6638285 | Gabbay | Oct 2003 | B2 |
6669724 | Park et al. | Dec 2003 | B2 |
6673070 | Edwards et al. | Jan 2004 | B2 |
6679264 | Deem et al. | Jan 2004 | B1 |
6682250 | Banks | Jan 2004 | B2 |
6682520 | Ingenito | Jan 2004 | B2 |
6694979 | Deem et al. | Feb 2004 | B2 |
6709401 | Perkins et al. | Mar 2004 | B2 |
6712812 | Roschak et al. | Mar 2004 | B2 |
6716208 | Humes | Apr 2004 | B2 |
6722360 | Doshi | Apr 2004 | B2 |
6743259 | Ginn | Jun 2004 | B2 |
6746686 | Hughes et al. | Jun 2004 | B2 |
6749606 | Keast et al. | Jun 2004 | B2 |
6840952 | Saker et al. | Jan 2005 | B2 |
6849049 | Starr et al. | Feb 2005 | B2 |
6849084 | Rabkin et al. | Feb 2005 | B2 |
6860847 | Alferness et al. | Mar 2005 | B2 |
6887256 | Gilson | May 2005 | B2 |
6904909 | Andreas et al. | Jun 2005 | B2 |
6929637 | Gonzalez et al. | Aug 2005 | B2 |
6941950 | Wilson et al. | Sep 2005 | B2 |
6951571 | Srivastava | Oct 2005 | B1 |
6958076 | Acosta et al. | Oct 2005 | B2 |
6989027 | Allen et al. | Jan 2006 | B2 |
6997951 | Solem et al. | Feb 2006 | B2 |
7011094 | Rapacki et al. | Mar 2006 | B2 |
7100616 | Springmeyer | Sep 2006 | B2 |
7141046 | Perkins et al. | Nov 2006 | B2 |
7175644 | Cooper et al. | Feb 2007 | B2 |
7207946 | Sirokman | Apr 2007 | B2 |
7252086 | Tanaka | Aug 2007 | B2 |
7278430 | Kumar | Oct 2007 | B2 |
7357795 | Kaji et al. | Apr 2008 | B2 |
7412977 | Fields et al. | Aug 2008 | B2 |
7434578 | Dillard et al. | Oct 2008 | B2 |
7476203 | DeVore et al. | Jan 2009 | B2 |
7530995 | Quijano et al. | May 2009 | B2 |
7533671 | Gonzalez et al. | May 2009 | B2 |
7757692 | Alferness et al. | Jul 2010 | B2 |
7798974 | Sirokman | Sep 2010 | B2 |
7842010 | Bonnette et al. | Nov 2010 | B2 |
7842061 | Dillard et al. | Nov 2010 | B2 |
7875048 | Dillard et al. | Jan 2011 | B2 |
20010010017 | Letac et al. | Jul 2001 | A1 |
20010025132 | Alferness et al. | Sep 2001 | A1 |
20010034518 | Edwards et al. | Oct 2001 | A1 |
20010037808 | Deem et al. | Nov 2001 | A1 |
20010041906 | Gonzalez | Nov 2001 | A1 |
20010051799 | Ingenito | Dec 2001 | A1 |
20010052344 | Doshi | Dec 2001 | A1 |
20010056274 | Perkins et al. | Dec 2001 | A1 |
20020007831 | Davenport et al. | Jan 2002 | A1 |
20020029004 | Starr et al. | Mar 2002 | A1 |
20020052626 | Gilson | May 2002 | A1 |
20020062120 | Perkins et al. | May 2002 | A1 |
20020077564 | Campbell et al. | Jun 2002 | A1 |
20020077593 | Perkins et al. | Jun 2002 | A1 |
20020077696 | Zadno-Azizi et al. | Jun 2002 | A1 |
20020087153 | Roschak et al. | Jul 2002 | A1 |
20020095209 | Zadno-Azizi et al. | Jul 2002 | A1 |
20020111619 | Keast et al. | Aug 2002 | A1 |
20020111620 | Cooper et al. | Aug 2002 | A1 |
20020112729 | DeVore et al. | Aug 2002 | A1 |
20020123749 | Jain | Sep 2002 | A1 |
20020138135 | Duerig et al. | Sep 2002 | A1 |
20020147462 | Mair et al. | Oct 2002 | A1 |
20030018327 | Truckai et al. | Jan 2003 | A1 |
20030018344 | Kaji et al. | Jan 2003 | A1 |
20030024527 | Ginn | Feb 2003 | A1 |
20030050648 | Alferness et al. | Mar 2003 | A1 |
20030051733 | Kotmel et al. | Mar 2003 | A1 |
20030055331 | Kotmel et al. | Mar 2003 | A1 |
20030070682 | Wilson et al. | Apr 2003 | A1 |
20030083671 | Rimbaugh et al. | May 2003 | A1 |
20030109869 | Shadduck | Jun 2003 | A1 |
20030125763 | McInnes | Jul 2003 | A1 |
20030127090 | Gifford et al. | Jul 2003 | A1 |
20030154988 | DeVore et al. | Aug 2003 | A1 |
20030158515 | Gonzalez et al. | Aug 2003 | A1 |
20030167065 | Kumar | Sep 2003 | A1 |
20030180922 | Eaton et al. | Sep 2003 | A1 |
20030181922 | Alferness | Sep 2003 | A1 |
20030183235 | Rimbaugh et al. | Oct 2003 | A1 |
20030195385 | DeVore | Oct 2003 | A1 |
20030212337 | Sirokman | Nov 2003 | A1 |
20030212412 | Dillard et al. | Nov 2003 | A1 |
20030216769 | Dillard et al. | Nov 2003 | A1 |
20030225445 | Derus et al. | Dec 2003 | A1 |
20030228344 | Fields et al. | Dec 2003 | A1 |
20040039250 | Tholfsen et al. | Feb 2004 | A1 |
20040059263 | DeVore | Mar 2004 | A1 |
20040127912 | Rabkin et al. | Jul 2004 | A1 |
20040143282 | Dillard et al. | Jul 2004 | A1 |
20040167636 | Dillard et al. | Aug 2004 | A1 |
20040206349 | Alferness et al. | Oct 2004 | A1 |
20040210248 | Gordon et al. | Oct 2004 | A1 |
20040211412 | Alferness et al. | Oct 2004 | A1 |
20040243140 | Alferness et al. | Dec 2004 | A1 |
20040244802 | Tanaka | Dec 2004 | A1 |
20050033310 | Alferness et al. | Feb 2005 | A1 |
20050033344 | Dillard et al. | Feb 2005 | A1 |
20050096721 | Mangin et al. | May 2005 | A1 |
20050137611 | Escudero et al. | Jun 2005 | A1 |
20050145253 | Wilson et al. | Jul 2005 | A1 |
20050166925 | Wilson et al. | Aug 2005 | A1 |
20050222580 | Gifford et al. | Oct 2005 | A1 |
20050267323 | Dorros et al. | Dec 2005 | A1 |
20060074382 | Gonzalez et al. | Apr 2006 | A1 |
20060235467 | DeVore | Oct 2006 | A1 |
20060270940 | Tsukashima et al. | Nov 2006 | A1 |
20070221230 | Thompson et al. | Sep 2007 | A1 |
20070225747 | Perkins et al. | Sep 2007 | A1 |
20080015627 | DeVore | Jan 2008 | A1 |
20080132989 | Snow et al. | Jun 2008 | A1 |
20090099530 | Adams et al. | Apr 2009 | A1 |
20090182369 | Gonzalez | Jul 2009 | A1 |
20090292262 | Adams et al. | Nov 2009 | A1 |
20100256714 | Springmeyer | Oct 2010 | A1 |
20100262071 | Kutsko et al. | Oct 2010 | A1 |
Number | Date | Country |
---|---|---|
2002239759 | May 2002 | AU |
2004263132 | Oct 2010 | AU |
2308186 | May 1999 | CA |
2375752 | Jan 2001 | CA |
2401331 | Mar 2001 | CA |
2408923 | Nov 2001 | CA |
101868199 | Oct 2010 | CN |
10004979 | Aug 2000 | DE |
0665029 | Aug 1995 | EP |
0743071 | Nov 1996 | EP |
1151729 | Nov 2001 | EP |
1157663 | Nov 2001 | EP |
106276 | May 2002 | EP |
1198269 | Oct 2009 | EP |
03 716 212 | Dec 2010 | EP |
2 082 071 | Mar 1982 | GB |
324 729 | Nov 1998 | GB |
2348138 | Sep 2000 | GB |
58-163332 | Sep 1983 | JP |
60-10740 | Jan 1994 | JP |
2003-503162 | Jan 2003 | JP |
2003-533266 | Nov 2003 | JP |
2004-535887 | Dec 2004 | JP |
2005-527297 | Sep 2005 | JP |
3742010 | Nov 2005 | JP |
4387803 | Oct 2009 | JP |
2140211 | Oct 1999 | RU |
852321 | Jul 1981 | SU |
1371700 | Feb 1988 | SU |
1593651 | Sep 1990 | SU |
WO 8809683 | Dec 1988 | WO |
WO 9426175 | Nov 1994 | WO |
WO 9532018 | Nov 1995 | WO |
WO 9634582 | Nov 1996 | WO |
WO 9637167 | Nov 1996 | WO |
WO 9709932 | Mar 1997 | WO |
WO 9713471 | Apr 1997 | WO |
WO 9727893 | Aug 1997 | WO |
WO 9742871 | Nov 1997 | WO |
WO 9744085 | Nov 1997 | WO |
WO 9800840 | Jan 1998 | WO |
WO 9801084 | Jan 1998 | WO |
WO 9819633 | May 1998 | WO |
PCTUS9818366 | Sep 1998 | WO |
WO 9839047 | Sep 1998 | WO |
WO 9844854 | Oct 1998 | WO |
WO 9848706 | Nov 1998 | WO |
WO 9901076 | Jan 1999 | WO |
WO 9913801 | Mar 1999 | WO |
WO 9926692 | Jun 1999 | WO |
WO 9932040 | Jul 1999 | WO |
WO 9942059 | Aug 1999 | WO |
WO 9942161 | Aug 1999 | WO |
WO 9959503 | Nov 1999 | WO |
WO 9964109 | Dec 1999 | WO |
WO 0018329 | Apr 2000 | WO |
WO 0027292 | May 2000 | WO |
WO 0042950 | Jul 2000 | WO |
WO 0051500 | Sep 2000 | WO |
WO 0051510 | Sep 2000 | WO |
WO 0062699 | Oct 2000 | WO |
WO 0078386 | Dec 2000 | WO |
WO 0078407 | Dec 2000 | WO |
WO 0102042 | Jan 2001 | WO |
WO 0103641 | Jan 2001 | WO |
WO 0103642 | Jan 2001 | WO |
WO 0105334 | Jan 2001 | WO |
WO 0110313 | Feb 2001 | WO |
WO 0110314 | Feb 2001 | WO |
WO 0112104 | Feb 2001 | WO |
WO 0113839 | Mar 2001 | WO |
WO 0113908 | Mar 2001 | WO |
WO 0128433 | Apr 2001 | WO |
WO 0130266 | May 2001 | WO |
WO 0137897 | May 2001 | WO |
WO 0145590 | Jun 2001 | WO |
WO 0149213 | Jul 2001 | WO |
WO 0152775 | Jul 2001 | WO |
WO 0154585 | Aug 2001 | WO |
WO 0154625 | Aug 2001 | WO |
WO 0154685 | Aug 2001 | WO |
WO 0166190 | Sep 2001 | WO |
WO 0170114 | Sep 2001 | WO |
WO 0174271 | Oct 2001 | WO |
WO 0187170 | Nov 2001 | WO |
WO 0189366 | Nov 2001 | WO |
WO 0195786 | Dec 2001 | WO |
WO 0205884 | Jan 2002 | WO |
PCTUS0128360 | Mar 2002 | WO |
WO 0222072 | Mar 2002 | WO |
WO 0232333 | Apr 2002 | WO |
WO 0234322 | May 2002 | WO |
WO 0238038 | May 2002 | WO |
WO 0247575 | Jun 2002 | WO |
WO 02056794 | Jul 2002 | WO |
WO 02064045 | Aug 2002 | WO |
WO 02064190 | Aug 2002 | WO |
WO 02069823 | Sep 2002 | WO |
WO 02094087 | Nov 2002 | WO |
WO 03022124 | Mar 2003 | WO |
WO 03030975 | Apr 2003 | WO |
WO 03003946 | May 2003 | WO |
WO 03034927 | May 2003 | WO |
WO 03041779 | May 2003 | WO |
WO 03047468 | Jun 2003 | WO |
WO 03078579 | Sep 2003 | WO |
WO 03088820 | Oct 2003 | WO |
WO 03094996 | Nov 2003 | WO |
WO 03099164 | Dec 2003 | WO |
WO 2004010845 | Feb 2004 | WO |
WO 2004080347 | Sep 2004 | WO |
WO 2004244802 | Dec 2004 | WO |
WO 2005013835 | Feb 2005 | WO |
WO 2007123690 | Nov 2007 | WO |
WO 2009049261 | Apr 2009 | WO |
WO 2010118056 | Oct 2010 | WO |
Number | Date | Country | |
---|---|---|---|
20060074382 A1 | Apr 2006 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10317667 | Dec 2002 | US |
Child | 11204383 | US | |
Parent | 10081712 | Feb 2002 | US |
Child | 10317667 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10178073 | Jun 2002 | US |
Child | 10081712 | US |